<DOC>
	<DOCNO>NCT02821715</DOCNO>
	<brief_summary>This Phase 2 study 3-site , double-blind , randomised , placebo-controlled , 3-way cross-over trial , involve 3 treatment Modafinil 300 mg combination drug THN102 ( Modafinil/Flecainide 300 /3 mg , Modafinil/Flecainide 300 /27 mg ) .</brief_summary>
	<brief_title>Safety Efficacy THN102 Sleepiness Narcoleptic Patients</brief_title>
	<detailed_description>The 3 double blind period ( 2-week ) follow stabilisation period modafinil 300 mg/day ( open , 2-week ) follow one-week washout period modafinil dose .</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Main inclusion Criteria : Patients diagnosis narcolepsy type 1 ( i.e . cataplexy ) type 2 ( without cataplexy ) accord International Classification Sleep Disorders ( ICSD3 ) criterion . Body mass index &gt; 18 kg/m2 &lt; 35 kg/m2 . Patients treat modafinil stable dosage least 2 month still complain excessive daily somnolence ( EDS ) despite treatment Epworth Sleepiness Scale ( ESS ) score ≥ 14/24 baseline period . Main exclusion Criteria : Patients untreated sleep apnea syndrome ( respiratory disorder index &gt; 30/h ) cause daytime sleepiness assess patient history . Psychiatric neurological disorder , narcolepsy/cataplexy , Parkinson 's disease , Alzheimer 's disease , Huntington 's Chorea , multiple sclerosis , moderate severe psychosis dementia , bipolar illness , epilepsy , severe clinical anxiety depression , Beck Depression Inventory ≥ 21 suicidal risk ( item &gt; 0 ) , problem investigator 's opinion would preclude patient 's participation completion trial comprise reliable representation subjective symptom . Contraindication flecainide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>